logo
Artificial Intelligence (AI) Titan Nvidia Has Scored a $4 Billion "Profit" in an Unexpected Way

Artificial Intelligence (AI) Titan Nvidia Has Scored a $4 Billion "Profit" in an Unexpected Way

Yahoo5 hours ago

Artificial intelligence (AI) is Wall Street's hottest trend, with graphics processing unit (GPU) colossus Nvidia at the heart of this revolution.
However, Nvidia is also an investor, with a portfolio of six stocks worth more than $1.1 billion at the end of March.
Nvidia's largest investment holding has rapidly climbed in value, but may already be in a bubble.
10 stocks we like better than Nvidia ›
For more than two years, no trend has been held in higher regard on Wall Street than the evolution of artificial intelligence (AI). With AI, software and systems are capable of making split-second decisions, overseeing generative AI solutions, and training large language models (LLMs), all without the need for human oversight.
The long-term potential for this game-changing technology is truly jaw-dropping. If the analysts at PwC are correct, a combination of consumption-side effects and productivity improvements from AI will add $15.7 trillion to the global economy by the turn of the decade.
Although a long list of hardware and software/system application companies have benefited immensely from the AI revolution, none stands out more than tech titan Nvidia (NASDAQ: NVDA). But what you might be surprised to learn is that this highly influential AI company has scored a $4 billion "profit" in an uncharacteristic manner.
It took less than two years for Nvidia to catapult from a $360 billion market cap to (briefly) the world's largest public company, with a valuation that handily surpassed $3.5 trillion. A $3 trillion-plus increase in valuation in such a short time frame had never been witnessed before.
Nvidia's claim to fame is its Hopper (H100) and next-generation Blackwell graphics processing units (GPUs), which are the undisputed top options deployed in AI-accelerated data centers. Orders for both chips have been extensively backlogged, despite the efforts of world-leading chip fabrication company Taiwan Semiconductor Manufacturing to boost its chip-on-wafer-on-substrate monthly wafer capacity.
When demand for a good or service outstrips its supply, the law of supply and-demand states that prices will climb until demand tapers. Whereas direct rival Advanced Micro Devices was netting anywhere from $10,000 to $15,000 for its Instinct MI300X AI-accelerating chip early last year, Nvidia's Hopper chips were commanding a price point that topped $40,000. The ability to charge a premium for its AI hardware, due to a combination of strong demand and persistent AI-GPU scarcity, helped push Nvidia's gross margin into the 70% range.
Nvidia CEO Jensen Huang is also intent on keeping his company at the forefront of the innovative curve. He's aiming to bring a new advanced chip to market each year, with Blackwell Ultra (2025), Vera Rubin (2026), and Vera Rubin Ultra (2027) set to follow in the path of Hopper and Blackwell. In other words, it doesn't appear as if Nvidia will cede its compute advantages anytime soon.
The final piece of the puzzle for Nvidia has been its CUDA software platform. This is what assists developers in maximizing the compute abilities of their Nvidia GPUs, as well as aids with building/training LLMs. CUDA has played a pivotal role in keeping clients loyal to Nvidia's ecosystem of products and services.
Collectively, Nvidia's data center segment has helped catapult sales by 383% between fiscal 2023 (ended in late January 2023) and fiscal 2025, and sent adjusted net income skyrocketing from $8.4 billion to $74.3 billion over the same timeline.
As you can imagine, most of Nvidia's more than $74 billion in adjusted net income last year was derived from its operating activities -- and this is how it should be for a market-leading growth stock. But it's not the only way Wall Street's AI darling can put dollars in the profit column.
What's often overlooked about Nvidia is that it's also an investor. Just as institutional money managers with more than $100 million in assets under management (AUM) are required to file Form 13F no later than 45 days following the end to a quarter -- a 13F lays out which stocks, exchange-traded funds (ETFs), and select options were purchased and sold -- businesses with north of $100 million in AUM must do the same. This includes Nvidia.
At the end of March, Nvidia had more than $1.1 billion invested across a half-dozen publicly traded companies. Accounting rules require Nvidia to recognize unrealized gains and losses each quarter, based on the change in value of the securities in its investment portfolio.
Nvidia's largest investment holding is AI-data center infrastructure goliath CoreWeave (NASDAQ: CRWV), which went public in late March. Nvidia made an initial investment in CoreWeave of $100 million in April 2023, and upped its stake by another $250 million in March 2025, prior to its initial public offering (IPO). On a combined basis, Nvidia has put $350 million of its capital to work in Wall Street's hottest IPO.
As of the closing bell on Friday, June 20, the 24,182,460 shares of CoreWeave that Nvidia held, as of March 31, were worth (drumroll) close to $4.44 billion. On an unrealized basis, Wall Street's AI titan is sitting on a $4 billion-plus "profit" from its investment.
If you're wondering why "profit" is in quotations, it's because Nvidia may have reduced its stake in CoreWeave since the second quarter began. We won't know for sure until 13Fs detailing second-quarter trading activity are filed in mid-August. Further, this $4 billion unrealized gain can fluctuate, depending on where CoreWeave stock closes out the June quarter. Nevertheless, it's been one heck of a windfall for Nvidia.
While Nvidia has a solid track record of making smart investments in up-and-coming tech companies -- many of which it's partnered with -- there's also the real possibility it's playing with fire when it comes to CoreWeave.
Don't get me wrong, CoreWeave has been a fantastic client for Nvidia. It purchased 250,000 Hopper GPUs for its AI-data centers, which it leases out to businesses looking for compute capacity. It's in Nvidia's best interest that CoreWeave succeed and upgrade its AI chips roughly twice per decade.
But there are a number of red flags with CoreWeave that suggest its $88 billion valuation isn't sustainable.
One of the biggest concerns with Wall Street's hottest IPO is that Nvidia's aggressive innovation cycles could hinder, not help, its business. Bringing an advanced AI chip to market annually has the potential to quickly depreciate CoreWeave's Hopper GPUs, and might send customers to rival data centers that have newer chips. When CoreWeave looks to upgrade its infrastructure in the coming years, there's a very good chance it'll recoup far less from its assets than it expects.
CoreWeave has also leaned on leverage to build out its AI-data center. Relying on debt to acquire GPUs can lead to burdensome debt-servicing costs. For the moment, these servicing costs are adding to the company's steep operating losses.
Valuation is another clear concern with CoreWeave. Investors are paying roughly 8 times forecast sales in 2026 for a company that's not time-tested and hasn't generated a profit.
While Nvidia, undoubtedly, wants to see CoreWeave succeed, locking in its gains at these levels would make a lot of sense.
Before you buy stock in Nvidia, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $689,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $906,556!*
Now, it's worth noting Stock Advisor's total average return is 809% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 23, 2025
Sean Williams has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Nvidia, and Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy.
Artificial Intelligence (AI) Titan Nvidia Has Scored a $4 Billion "Profit" in an Unexpected Way was originally published by The Motley Fool

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SBC Medical added to membership of Russell 3000 ® Index
SBC Medical added to membership of Russell 3000 ® Index

Business Wire

timean hour ago

  • Business Wire

SBC Medical added to membership of Russell 3000 ® Index

IRVINE, Calif.--(BUSINESS WIRE)-- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical'), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000 ® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. Membership in the Russell 3000 ® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 ® Index or small-cap Russell 2000 ® Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. Fiona Bassett, CEO of FTSE Russell, An LSEG Business, comments: 'The Russell indexes have continuously adapted to the evolving dynamic US economy, and it's crucial to fully recalibrate the suite of Russell US Indexes, ensuring the indexes maintain an accurate representation of the market. The transition to a semi-annual reconstitution frequency from 2026 will ensure our indexes continue to represent the market and maintain the purpose of the index as a portfolio benchmark.' For more information on the Russell 3000 ® Index and the Russell indexes reconstitution, go to the 'Russell Reconstitution' section on the FTSE Russell website. About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit About FTSE Russell, an LSEG Business FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit FTSE Russell. Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' 'targets' or 'hopes' or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading 'Risk Factors' and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the 'SEC'), which are accessible on the SEC's website at

What Tariffs? Nasdaq, S&P 500 Climb to Record Highs as Netflix, Disney Continue Huge Runs
What Tariffs? Nasdaq, S&P 500 Climb to Record Highs as Netflix, Disney Continue Huge Runs

Yahoo

timean hour ago

  • Yahoo

What Tariffs? Nasdaq, S&P 500 Climb to Record Highs as Netflix, Disney Continue Huge Runs

The Great Tariff Panic of 2025 that gripped Wall Street in April? It appears in the rearview mirror now, with the S&P 500 and Nasdaq closing at new all-time highs on Friday. A number of prominent media and tech companies have been riding the wave to fresh highs as well, with Netflix increasing 1.26% and closing at a company-record $1,323.12 per share on Friday — a day after setting its previous high mark. The streaming heavyweight's stock price is up 54% since early April. Disney, Warner Bros. Discovery, Fox Corp. and Paramount all made minor gains on Friday, continuing recent climbs that started following Wall Street's April downturn. WBD and Disney's shares are up about 50% since early April, while Fox Corp. and Paramount have both made roughly 20% gains since then. The S&P 500 jumped 0.52% and closed Friday at 6,173, surpassing its previous all-time high of 6,144, which was set in February; the tech-heavy Nasdaq, meanwhile, posted an identical percentage increase and closed at 20,273, topping its record high that was set last December. Amazon and Alphabet, Google's parent company, each gained more than 2% on Friday, while Apple closed slightly higher. Apple has mostly rebounded to where it was before President Donald Trump announced his 'Liberation Day' tariffs in early April — a plan that initially rocked Wall Street and shaved more than $500 billion from Apple's market cap in the days following his announcement. 'We're going to have a booming stock market for a long time, because we're reinvesting in the United States of America,' Trump said on April 4. That was not the case, at least at first, when the S&P 500 and Nasdaq took its biggest hits since COVID smacked the markets in 2020. The S&P 500 is now up more than 20% and the Nasdaq has surged 32% since the day after Trump's tariff plan was announced. On Friday, Trump addressed the upcoming July 9 deadline on the pause he put on his stiffest tariffs, during a press conference in which he lauded the Supreme Court for limiting nationwide injunctions against executive orders. The president said he was not too concerned about the deadline when asked about it by one reporter. 'No, we can do whatever we want,' Trump said. 'We could extend it. We could make it shorter.' The post What Tariffs? Nasdaq, S&P 500 Climb to Record Highs as Netflix, Disney Continue Huge Runs appeared first on TheWrap. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

SINOVAC Board of Directors Prevails Against Advantech/Prime's Lawsuit in Hong Kong
SINOVAC Board of Directors Prevails Against Advantech/Prime's Lawsuit in Hong Kong

Business Wire

timean hour ago

  • Business Wire

SINOVAC Board of Directors Prevails Against Advantech/Prime's Lawsuit in Hong Kong

BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced it has prevailed against the latest lawsuit filed by Advantech/Prime Success ('Advantech/Prime') in Hong Kong. This result follows Advantech/Prime's recently failed petition in New York last week, which was a repeated attempt by the purported PIPE Investors to block or delay a hearing for interim relief sought by the Company et al at the Antiguan High Court and to interfere with the payment of the US$55.00 per common share special cash dividend to valid shareholders of the Company as declared by the current SINOVAC Board. On June 24, Advantech/Prime delivered via email an ex parte Summons to SINOVAC, 1Globe Capital LLC ('1Globe') and OrbiMed Partners Master Fund Limited ('OrbiMed') for an 'interim-interim' injunction application (the 'Application'). Vivo Capital also sought to join the Application on June 26. After the emergent hearing at the High Court of Hong Kong on June 27, the court refused to grant any of the relief sought in the Summons. Among other things, the judge also criticized Advantech/Prime for: Failing to comply with the duty of full and frank disclosure in the Application; and The alleged urgency of the Application being self-induced by Advantech/Prime. The court also ordered that legal costs incurred in the Application by SINOVAC, 1Globe and OrbiMed be compensated by Advantech/Prime, with quantum to be assessed. Advantech/Prime's continued multi-jurisdictional lawfare is intended to interfere with rightful dividend payments to SINOVAC's valid shareholders and distract from its long history of self-serving schemes. These schemes include: Privatization attempt at a below-market price in 2016; Invalid PIPE transaction at a below-market price in 2018, which materially diluted SINOVAC shareholders and was made at a time when the Company did not need the capital; US$7.5 million debt investment into Sinovac Life Sciences Co., Ltd. ('SLS'), a wholly owned subsidiary of SINOVAC, in exchange for a 7.5% equity interest in SLS in 2020, at a time when the Company did not need the capital and which has resulted in over US$500 million of distributions made to Advantech/Prime to date while common shareholders have received nothing; and Baseless and wasteful legal action in 2025 to interfere with the dividend payment unless Advantech/Prime is able to double dip on dividends already received from SLS. The current SINOVAC Board remains committed to its mission of restoring fairness, delivering value, and protecting the rights of all valid shareholders. Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card ' AGAINST ' Proposal 1 to remove the current Board and ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S. and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store